Literature DB >> 14508317

Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery.

Nurgul Yurtseven1, Pelin Karaca, Mehmet Kaplan, Vedat Ozkul, Abdullah K Tuygun, Tamer Aksoy, Sevim Canik, Ercument Kopman.   

Abstract

BACKGROUND: The aim of this study was to investigate the postoperative hemodynamic effects of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery.
METHODS: Twenty patients who underwent mitral valve replacement surgery were included in the study. In the surgical intensive care unit, at T0 (before the inhalation of nitroglycerin), basal systemic and pulmonary hemodynamics were recorded. Then, 2.5 microg x kg-1 x min-1 nitroglycerin liquid nebulized by a 2-l gas flow of 40% oxygen and air mixture was administered to the patients who were diagnosed as having pulmonary hypertension (mean pulmonary arterial pressures > 25 mmHg). The same parameters were measured at the first (T1), third (T2), and fifth (T3) hours after the beginning of this treatment and 1 h after the end of nitroglycerin inhalation (T4).
RESULTS: There were no statistically significant differences at T0, T1, T2, T3, or T4 with respect to heart rate, mean arterial pressure, systemic vascular resistance, cardiac index, mixed venous oxygen saturation, arteriovenous oxygen content difference, or arterial carbon dioxide tension. However, mean pulmonary artery pressure, pulmonary vascular resistance, and intrapulmonary shunt fraction were significantly lower, and the arterial oxygen tension/fraction of inspired oxygen ratio was higher at T1, T2, and T3 when compared to that of T0 and T4.
CONCLUSION: The results suggest that nitroglycerin inhalation produces a significant reduction in both mean pulmonary artery pressure and pulmonary vascular resistance in patients after mitral valve operations without reducing mean arterial pressure and systemic vascular resistance. Therefore, it might be a safe and useful therapeutic intervention during the postoperative course.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508317     DOI: 10.1097/00000542-200310000-00017

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Is nitroglycerin effective in treatment of haemoptysis?

Authors:  Yi-pin Zhou; Qi Guo; Xiao-ke Chen; Guo Huang
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 2.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 3.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 4.  Inhaled therapy for the management of perioperative pulmonary hypertension.

Authors:  C A Thunberg; S T Morozowich; Harish Ramakrishna
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

5.  Pentaerythritol Tetranitrate In Vivo Treatment Improves Oxidative Stress and Vascular Dysfunction by Suppression of Endothelin-1 Signaling in Monocrotaline-Induced Pulmonary Hypertension.

Authors:  Sebastian Steven; Matthias Oelze; Moritz Brandt; Elisabeth Ullmann; Swenja Kröller-Schön; Tjebo Heeren; Lan P Tran; Steffen Daub; Mobin Dib; Dirk Stalleicken; Philip Wenzel; Thomas Münzel; Andreas Daiber
Journal:  Oxid Med Cell Longev       Date:  2017-02-28       Impact factor: 6.543

6.  Nebulized Nitroglycerin for Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome: A Case Report.

Authors:  Benjamin T Daxon; Erin Lark; Luke J Matzek; Amanda R Fields; Kyle J Haselton
Journal:  A A Pract       Date:  2021-02-05

Review 7.  Arterial pulmonary hypertension in noncardiac intensive care unit.

Authors:  Mykola V Tsapenko; Arseniy V Tsapenko; Thomas Bo Comfere; Girish K Mour; Sunil V Mankad; Ognjen Gajic
Journal:  Vasc Health Risk Manag       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.